{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:44:39Z","timestamp":1794890679490,"version":"4.9.1"},"reference-count":11,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This analysis was conducted to assess exposure\u2013response relationships for efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor. Efficacy was assessed categorically by overall response rate (ORR) with Response Evaluation Criteria in Solid Tumors version 1.1 and longitudinally (changes in tumor size and volume). Safety included hepatic parameters (i.e., alanine aminotransferase [ALT], aspartate aminotransferase [AST], and total bilirubin). Average pexidartinib concentration (C<jats:sub>avg<\/jats:sub>) was identified as the primary exposure parameter correlated with response. In categorical and longitudinal analyses, higher C<jats:sub>avg<\/jats:sub> coincided with greater ORR and tumor size reduction, respectively, with smaller joint size having a greater impact. For safety, a significant relationship was observed between C<jats:sub>avg<\/jats:sub> and incidence of ALT\u2010related and AST\u2010related adverse events (AEs). With increased exposure, an increase in efficacy was predicted with near maximum effect at 800\u00a0mg\/day. Higher initial dose (1000\u00a0mg\/day) during the first 2\u00a0weeks did not improve efficacy. Higher doses were associated with an increased risk of ALT\u2010related and AST\u2010related AEs. These results support the US Food and Drug Administration\u2013approved dose (400\u00a0mg two times\/day without initial loading dose).<\/jats:p>","DOI":"10.1002\/psp4.12712","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T09:06:46Z","timestamp":1632906406000},"page":"1422-1432","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Exposure\u2013response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor"],"prefix":"10.1002","volume":"10","author":[{"given":"Ophelia","family":"Yin","sequence":"first","affiliation":[{"name":"Quantitative Clinical Pharmacology and Translational Sciences Daiichi Sankyo, Inc. Basking Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamim","family":"Zahir","sequence":"additional","affiliation":[{"name":"Quantitative Clinical Pharmacology and Translational Sciences Daiichi Sankyo, Inc. Basking Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"French","sequence":"additional","affiliation":[{"name":"Metrum Research Group Tariffville Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Polhamus","sequence":"additional","affiliation":[{"name":"Metrum Research Group Tariffville Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[{"name":"Metrum Research Group Tariffville Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel","family":"van de Sande","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Leiden University Medical Center Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Tap","sequence":"additional","affiliation":[{"name":"Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[{"name":"Medical Oncology Leiden University Medical Center Leiden Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Dana\u2010Farber Cancer Institute Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Healey","sequence":"additional","affiliation":[{"name":"Orthopaedic Service Memorial Sloan Kettering Cancer Center New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Greenberg","sequence":"additional","affiliation":[{"name":"Global Oncology R&amp;D Daiichi Sankyo, Inc. Basking Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Shuster","sequence":"additional","affiliation":[{"name":"Global Oncology R&amp;D Daiichi Sankyo, Inc. Basking Ridge New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stacchiotti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fondazione IRCCS Instituto Nazionale dei Tumori Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.8482"},{"key":"e_1_2_11_3_1","volume-title":"Turalio (pexidartinib) capsules, for oral use [prescribing information]","author":"Daiichi Sankyo, Inc","year":"2020"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411366"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30764-0"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1753"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.12"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1011555016423"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1214\/17-EJS1337SI"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2931-4"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.16"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12258"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12712","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.12712","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12712","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T03:47:22Z","timestamp":1693194442000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":11,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/psp4.12712"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12712","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,14]]},"assertion":[{"value":"2021-06-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}